AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05602727
Drug: MK-1942
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-1942 oral capsule
Trial: NCT05602727
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral capsule
Trial: NCT05834582
Drug: Epirubicin+Cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin+Cyclophosphamide
Trial: NCT05672082
Drug: [18F]DPA-714
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participant received one injection of 200 MBq of \[18F\]DPA-714
Trial: NCT04890522
Drug: Triprilimab(JS001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maximum 6 cycles for combined therapy and maintenance for up to 2 years.
Trial: NCT00004442
Drug: chenodeoxycholic acid
RxNorm normalized name: Chenodeoxycholic acid
DrugBank: Chenodeoxycholic acid (DB06777)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04939701
Drug: ASP0739
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV)
Trial: NCT05622916
Drug: Topical Ethanol Extract (Piper crocatum)
RxNorm normalized name: ethanol Topical Foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ethanol extract of red betel leaves (Piper crocatum) 30% with the details of formulation on detailed description section
Trial: NCT05622916
Drug: Trichloroacetic Acid Topical
RxNorm normalized name: trichloroacetic acid topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trichloroacetic acid topical 90%
Trial: NCT05043922
Drug: CYH33
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: a Selective PI3Kα Inhibitor
Trial: NCT04730193
Drug: Caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine, also known as Trimethylxanthine, will be purchased through the University of Oklahoma Health Sciences Pharmacy and formulated into capsule pills containing 100mg of active ingredient
Trial: NCT04763083
Drug: NVG-111
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open label, continuous iv infusion, escalating doses of NVG-111 for minimum 3 cycles
Trial: NCT06378684
Drug: Group 1: JW0104(Period 1), C2207(Period 2), JW0104 + C2207(Period 3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, Oral, QD for 10 Days, Washout period is more than 14 days after administration
Trial: NCT06378684
Drug: Group 2: JW0104 + C2207(Period 1), JW0104(Period 2), C2207(Period 3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, Oral, QD for 10 Days, Washout period is more than 14 days after administration
Trial: NCT02699138
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compounded sugar pill
Trial: NCT04940338
Drug: Bromfenac Ophthalmic 0.09% Ophthalmic Solution
RxNorm normalized name: bromfenac ophthalmic 0.09% ophthalmic solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical bromfenac (0.9 mg/mL) 2x daily 7 days before the surgery
Trial: NCT04940338
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical placebo (artificial tears substitute) 2x daily before the surgery
Trial: NCT05852704
Drug: Placebo Tab
RxNorm normalized name: PLACEBO TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo once daily for a minimum of seven days while awaiting scheduled CABG and up until discharge with a short interruption for surgery.
Trial: NCT05067153
Drug: Fragmin 5000 UNT in 0.2 ML Prefilled Syringe
RxNorm normalized name: Fragmin 5000 UNT in 0.2 ML Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 days postoperative prophylactic treatment.
Trial: NCT04662060
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match acebilustat administered orally once daily
Trial: NCT05630989
Drug: combination therapy with MEKi.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This cohort will receive combination therapy with MEKi.
Trial: NCT06007222
Drug: Non-antithrombotic group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antithrombotic agents will be administered after randomization until the end of the study period.
Trial: NCT05243563
Drug: Topical steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: self-applied topical steroid therapy using clobetasol propionate 0.05%
Trial: NCT04494451
Drug: Vit C
RxNorm normalized name: M-Vit Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vitamin C (25 mg/kg or max. 1.5 gram every 6 hourly) for maximum 5 day
Trial: NCT04494451
Drug: Standard medical Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iv antibiotics alone
Trial: NCT06122181
Drug: HS-10384-matched placebo tablets
RxNorm normalized name: PLACEBO TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple dosing of HS-10384-matched placebo orally in a fasting state
Trial: NCT05585307
Drug: bavtavirine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT05585307
Drug: B/F/TAF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT05585307
Drug: Standard of Care (Substudy 01)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral therapy, administered orally~Non-NNRTIs, examples: ABC/DTG/3TC; DTG plus (TAF or TDF) plus (FTC or 3TC)
Trial: NCT05585307
Drug: Standard of Care (Substudy 03)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral therapy, administered orally
Trial: NCT05686863
Drug: remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: remifentanil
Trial: NCT03612466
Drug: Neupogen Injectable Product
RxNorm normalized name: Neupogen Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants who require stem cell collection will be given Neupogen to help mobilize hematopoietic stem cells into the circulation for collection.
Trial: NCT04756622
Drug: N acetyl cysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N acetyl cysteine dissolved in water at a dose of 600 mg three times daily from day of transplant until neutrophil engraftment, or upon resolution of OM, whichever appears later.
Trial: NCT04799743
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo consist of mainly starch and microcrystalline cellulose, the usage and dosage are the same as the investigational drug.
Trial: NCT04854759
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg, capsule
Trial: NCT05275465
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Different dose levels of placebo
Trial: NCT06369961
Drug: transdermal fentanyl
RxNorm normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Adult cancer pain patients switched from oral opioid to TDF
Trial: NCT04844619
Drug: 4mg/ml KDR2-2 suspension eyedrop
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KDR2-2 is a synthetic anti-angiogenic chemical compound with highly effective inhibition on vascular endothelial growth factor receptor-2 (VEGFR2), and an additional, moderate inhibitory effect on platelet-derived growth factor receptor β (PDGFRβ).~KDR2-2 suspension eyedrop is developed for the treatment of iris neovascularization.
Trial: NCT04844619
Drug: 16mg/ml KDR2-2 suspension eyedrop
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KDR2-2 is a synthetic anti-angiogenic chemical compound with highly effective inhibition on vascular endothelial growth factor receptor-2 (VEGFR2), and an additional, moderate inhibitory effect on platelet-derived growth factor receptor β (PDGFRβ).~KDR2-2 suspension eyedrop is developed for the treatment of iris neovascularization.
Trial: NCT06202703
Drug: Pneumococcal Vaccine
RxNorm normalized name: PNEUMOCOCCAL VACCINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vaccination with pneumococcal vaccine (PCV13)
Trial: NCT06364787
Drug: Targeted drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-target kinase inhibitors can act on VEGFR-1,VEGFR-2,VEGFR-3,FGFR1,PDGFR,cKit,Ret and other targets.
Trial: NCT04683796
Drug: 100% Autologous serum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients' blood (36 ml per tube) will be collected in three 50-ml sterile centrifuge tubes. The tubes will be left standing in an upright position for 1-2 hours to enable blood clot formation at room temperature (18-25 C). The tubes will be centrifuged at 3000 g for 30 minutes at 20 C. The supernatant serum will be aseptically transferred into a sterile syringe to enable filtration through a 0.2 µm pore size membrane filter under a laminar air flow hood. A 1.5 ml aliquot of both final blood products will be transferred into identical opaque eye drop bottles, labelled name, hospital number, dated and sealed.
Trial: NCT04706897
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A loading infusion of the 50 ml syringe (A) containing normal saline was started at rate of 0.2 ml/ kg/hr ten minutes before induction (as masking for mixture in group S). Then anesthesia was induced with 2 mg/kg ideal body weight (IBW) of propofol , patients were intubated with the aid of 0.5 mg/kg IBW atracurium and received 0.1ml/kg from syringe (C) containing fentanyl (1mic/kg of IBW).
Trial: NCT06148103
Drug: Patients who received Dexmedetomodine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 microgram/kg over a period of 10 minutes, and then a maintenance infusion was titrated in a range from 0.2-1 μg/kg/h).
Trial: NCT06148103
Drug: patients who received propofol-fentanyl
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continued infusions of both fentanyl and propofol were 0.01-0.05 μg kg/ min 25-150 mg/h respectively.
Trial: NCT05978518
Drug: CPM Device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily device use
Trial: NCT04931368
Drug: Control intervention: four courses of MATRix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receive four courses of MATRix as induction treatment.
Trial: NCT05544591
Drug: 611 Q2W
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous injection, 600mg (loading dose, week 0) + 300mg Q2W (maintenance dose, from Week 2 to Week 14, 7 cycles)
Trial: NCT05544591
Drug: 611 Q4W
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous injection, 600mg (loading dose, Day1) + 300mg Q4W (maintenance dose, on week 4, 8, 12) + placebo Q4W (on week 2, 6, 10, 14)
Trial: NCT05544591
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous injection, Q2W, from Week 2 to Week 14, 7 cycles
Trial: NCT05133323
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching to Lu AG09222 will be administered per schedule specified in the arm.
Trial: NCT05484414
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo for SRP-3D (Diethylamide) Oral Suspension, 100 mg/mL
Trial: NCT05816772
Drug: Endosequence Bio ceramic Sealer
RxNorm normalized name: Bio-Kool
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brasseler,USA, a nano-particulate injectable premixed bioceramic sealer that contains Calcium Silicates, Calcium Phosphate, Calcium Hydroxide and Zirconium Oxide
Trial: NCT05681403
Drug: Improved BEAM regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitoxantrone hydrochloride liposome, carmostine, etoposide and cytarabine will be used as conditioning regimen for ASCT in the lymphoma patients.
Trial: NCT06418113
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 weeks post-surgery, temozolomide (TMZ) will be administered for 6 months
Trial: NCT05266040
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consistent with the pilot study VEII will use a random number generator to randomly assign a Manila packet containing amoxicillin 500mg + Placebo (empty capsule). Opaque medication packaging and using standardized verbal and written instructions helps ensure blindness of the VEII calibrated clinician, and patients of the therapeutic group they were assigned to.
Trial: NCT04766723
Drug: NT 201
RxNorm normalized name: Fluarix Quadrivalent 2013-2014
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
Trial: NCT04766723
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
Trial: NCT04682860
Drug: Hyoscine N Butylbromide
RxNorm normalized name: Hyoscine N butylbromide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyoscine N butylbromide injection for the treatment of abdominal pain in acute gastroenteritis
Trial: NCT06380205
Drug: Levonorgestrel/Ethinyl estradiol
RxNorm normalized name: levonorgestrel/ethinyl estradiol 0.1 mg-20 mcg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levonorgestrel/Ethinyl estradiol will be administered at protocol defined dose.
Trial: NCT04890548
Drug: AZD3427
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive 5 IA infusions of AZD3427 into the brachial artery. The IA infusions of AZD3427 will be administered via a syringe pump, using a polypropylene syringe containing 0.9% (w/v) saline and delivered through an administration set comprising a syringe, extension tubing (PVC), and a 0.2- or 0.22-μm PVDF syringe filter.
Trial: NCT04727528
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plabeco comparator
Trial: NCT05253794
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablet daily for 6 months
Trial: NCT06233799
Drug: iPLB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once per three weeks injections of placebo
Trial: NCT06233799
Drug: oPLB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral placebo tablets
Trial: NCT06491355
Drug: mfolfox6 and hlx04 regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the active comparator. only with mfolfox6 and hlx04 regimen treatment.
Trial: NCT05963347
Drug: CHOP Regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHOP will be administered in a 21-day cycle for a maximum of 6 cycles.
Trial: NCT06723171
Drug: IRX4204
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active Treatment
Trial: NCT00407017
Drug: Ketorolac LS
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00407017
Drug: Nepafenac
RxNorm normalized name: Nepafenac
DrugBank: Nepafenac (DB06802)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00407017
Drug: EconoPred Plus
RxNorm normalized name: Econopred Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06727630
Drug: PRJ1-3024
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRJ1-3024 is provided as capsules and is administered orally once a day
Trial: NCT05057689
Drug: Intranasal Fentanyl (2 mcg/kg)
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl 50 mcg/mL (concentration of 100 mcg/2 mL) will be atomized for intranasal administration at a dose of 2 mcg/kg (0.04 mL/kg) according to a weight-based dosing chart prior to laceration repair. The maximum dose will be 100 mcg.
Trial: NCT05720559
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid 0.4 mg/time, qd
Trial: NCT05720559
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine via orally on d2-d15 two times daily at a dose of 1000mg/m2 × patient 's body surface area.
Trial: NCT05161221
Drug: Naproxen 500 Mg
RxNorm normalized name: naproxen 500 MG
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participant will receive Naproxen 500 Mg post surgery for pain control
Trial: NCT05161221
Drug: Tylenol Pill
RxNorm normalized name: Tylenol Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be instructed to take up to 1000mg of Tylenol by mouth for pain control
Trial: NCT05113745
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets, taken twice daily
Trial: NCT05227118
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-8189 matching placebo administered orally QD
Trial: NCT05859711
Drug: saline mouth rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: saline mouth rinse 3 times per day starting in the 4th week of radiotherapy and for one month after completion of radiotherapy
Trial: NCT03997097
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients randomised in the group placebo in 3 oral doses of per day
Trial: NCT04481308
Drug: propofol (2 mg/kg) and fentanyl (1ug/kg) and 4 liters O2 flow through nasal cannula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: propofol (2 mg/kg) and fentanyl (1ug/kg) and 4 liters O2 flow through nasal cannula
Trial: NCT06381180
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plant will be vaporized.
Trial: NCT05532020
Drug: DCCR (diazoxide choline) extended-release tablets
RxNorm normalized name: choline Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All participants will be titrated over a four week period to the maintenance dose. Participants will take DCCR daily for up to 52 weeks.
Trial: NCT06158035
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: An initial infusion dose of prophylactic norepinephrine (6 ug) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 1 ug of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
Trial: NCT06109415
Drug: HTX-011
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg
Trial: NCT06109415
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400 mg
Trial: NCT06109415
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g
Trial: NCT06201039
Drug: 0.9% Normal Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prior to the end of neck dissection and any additional procedures, the bilateral catheter will be placed adjacent to the cervical plexus underneath the internal jugular vein, left in place for 72 hours and removed in a similar way to the Redon drainage by the surgeon. The CWI placebo will start immediately at a speed of 4ml/h containing 0.9% normal saline + 1:400000 adrenaline.
Trial: NCT02503163
Drug: KCT-0809 ophthalmic solution
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04608331
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled analgesia is provided for at least 24 hours but no more than 48 hours. The pump is established with morphine (0.5 mg/ml), in a total volume of 160 ml normal saline, and programmed to deliver 2-ml boluses at 6 to 8-minute lockout intervals with a background infusion rate of 1 ml/h.
Trial: NCT05586477
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A placebo pill (i.e., sugar) will be consumed 2 h before intervention.
Trial: NCT06610643
Drug: SOC
RxNorm normalized name: Isocet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care
Trial: NCT05846646
Drug: IMSA101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-tumoral administration once weekly for the first three weeks of Cycle 1 (Days 1, 8 and 15) and then on Day 1 of Cycles 2 and 3.
Trial: NCT04610138
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water
Trial: NCT06050291
Drug: Fixed-Dose Combination (FDC) Tablet
RxNorm normalized name: DYE FDC BLUE #1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Obicetrapib/Ezetimibe FDC tablet
Trial: NCT05710146
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 injection of 100mL of normal saline
Trial: NCT04847206
Drug: lysine-3,4-methylenedioxymethamphetamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A moderate dose of 171.7 mg lysine-MDMA will be administered.
Trial: NCT04847206
Drug: lysine-3,4-methylenedioxyamphetamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A moderate dose of 165.6 mg lysine-MDA will be administered.
Trial: NCT04762199
Drug: Flt3/MerTK Inhibitor MRX-2843
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT04826159
Drug: IMB-1018972
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified release tablet for oral administration
Trial: NCT05498766
Drug: Huaier granule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Huaier granule, oral administration, 10g each time, 3 times a day. Continuous medication until disease progression, the end of the study, intolerable toxicity, withdrawal from the study for any reason or death, or until the researcher determines that the participants will no longer benefit, whichever occurs first. After disease progression, whether to continue the medication or not should be determined by the researcher and participant together. Participants will start taking Huaier granule within 1 to 3 weeks after surgery.
Trial: NCT01882296
Drug: AGSPT_10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AGSPT 10mg for 7days administration
Trial: NCT01882296
Drug: AGSPT_20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AGSPT 20mg for 7days administration
Trial: NCT01882296
Drug: AGSPT_40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AGSPT 20mg x 2tablet for 7days administration